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Serum creatinine concentrations and estimated glomerular filtration rates (eGFR) 
are widely used for the evaluation of renal function. The Jaffe and enzymatic methods are 
the most common methods for creatinine measurement. The Jaffe method is commonly 
less expensive than enzymatic methods but may be more susceptible to interferences. 
Significant savings could be obtained if populations could be identified where the 
interference rate of the Jaffe method is acceptably low. The study objective was to 
compare creatinine and corresponding eGFR results from representative Jaffe and 
enzymatic creatinine methods in an outpatient population and determine the prevalence 
and magnitude of differences. 
This study analyzed 543 unique, randomly selected, outpatient samples. Samples 
were analyzed using both the Jaffe and enzymatic creatinine methods using an Abbott 
Architect c8000. eGFRs were calculated using the CKD-EPI and MDRD equations.  
Orthogonal (Deming) regression showed no significant difference between the 
two assays. The slope was 1.006 (95% CI: 0.998, 1.103) and the intercept was -0.005 
(95% CI: -0.015, 0.006). The average difference (bias) was -0.007 mg/dL. The Bland-
Altman limits of agreement (LOA) for the creatinine differences were -0.139 and 0.136 
mg/dL.  Of the CKD-EPI eGFR discrepancies, 3.1% resulted in a reclassification at the 
60 mL/min/1.73m2 decision limit.  The difference between the predicted and actual CKD-
EPI discordance at the 60 mL/min/1.73m2 decision limit was not statistically significant 




reclassification at the 60 mL/min/1.73m2 decision limit. The difference between the 
predicted and actual MDRD discordance at the 60 mL/min/1.73m2 decision limit was not 
statistically significant (χ!! = 0.31, p=0.76). 
Discrepancies in the CKD-EPI and MDRD eGFRs based on the Jaffe method did 
not result in a statistically significant increase in disease reclassifications at the 60 
mL/min/1.73m2 decision limit in an outpatient population.  The number of discordant 
eGFR results slightly varied by what discordance criteria was used.  An equal number of 
discordances were observed with the MDRD and CKD-EPI equations when eGFR were 
based upon measurement error (217 of 543). When discordance criteria was based upon 
observed differences (Bland-Altman), the MDRD equation showed slightly more 
discordances (26 of 543) compared to the CKD-EPI (21 of 543).  Studies are needed to 
characterize the relative rate of interference in additional populations. 
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What is Creatinine? 
 
Non-protein nitrogen (NPN) measurements have long been utilized to assess renal 
function as well as other clinical conditions. In the early part of the 20th century, NPN 
was used to describe those nitrogen containing compounds that remained in a filtrate after 
the proteins had been removed by precipitation. NPNs are now defined as nonprotein  
nitrogen containing compounds found in the blood.[1]  
Creatinine is a NPN compound found in the blood and accounts for 1-2% of all 
NPN compounds. Creatinine is a waste product of creatine and phosphocreatine. Creatine 
is synthesized in the liver and pancreas, where it is released into the bloodstream and 
taken up by various tissues, particularly muscles and the brain. Within the tissues, the 
enzyme creatine kinase catalyzes the conversion of creatine to phosphocreatine, which 
acts as a form of energy storage. During activity, phosphocreatine converts to creatinine 
by removal of an inorganic phosphate. The creatinine is released into the bloodstream, 
where it is filtered and removed by glomerular filtration within the kidneys and released 
into the urine. The amount of creatinine formed daily is proportional to an individual’s 
lean muscle mass and is released into circulation at a constant rate.[1] 
 Plasma creatinine concentration is the most widely used method for the evaluation 
of renal function.  Plasma creatinine is used to diagnose and monitor acute and chronic 
renal disease, estimate glomerular filtration rate, and assess the status of renal dialysis 
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patients. Urine creatinine analysis is used to calculate creatinine clearance, confirm 
completeness of 24-hour urine collections, and serve as a reference quantity for other 
analytes, such as in the calculation of the albumin/creatinine ratio.[2-4]  Several factors 
make creatinine a suitable compound for the evaluation of renal function: 1) plasma 
concentration is  relatively constant , 2) it is completely cleared from the plasma at the 
glomeruli, 3) it is not reabsorbed by the tubules, and 4) it is convenient and inexpensive 
to measure.[1, 4] Limitations to creatinine measurements are variation due to age, gender, 
exercise, sample interferences, muscle mass,  tubular secretion of creatinine causing an 
overestimation of creatinine clearance (7 to 10 percent increase), and individual diet may 
cause greater variation of creatinine excretion.[4] 
 
Testing Methodology for Creatinine 
 
 The Jaffe and enzymatic methods are the most commonly used methods for 
measuring creatinine concentrations. Most routine creatinine assays in current use have 
evolved from the reaction first described by Jaffe in 1886.[5] The Jaffe method uses 
alkaline picrate to react with creatinine for analytical measurement. At an alkaline pH, 
creatinine in the sample reacts with picrate to form a creatinine-picrate complex. The 
creatinine-picrate complex absorbs light at wavelengths near 500 nm. The rate of increase 
in absorbance is directly proportional to the concentration of creatinine in the sample.[3] 
 Although it is widely used, the Jaffe method is subject to nonspecificity bias. The 
nonspecificity bias occurs when the Jaffe reagent reacts with other substances within the 
matrix being tested. To account for the sensitivity of Jaffe methods to noncreatinine 
chromogens, some manufacturers have adjusted the calibration to minimize the non-
specificity bias and produce results more closely aligned with reference methods. 
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Recalibration is performed by subtracting a constant value from the result to compensate 
for nonspecific chromogens. The constant value is a fixed concentration that is 
automatically subtracted from each result. The constant value is predetermined by the 
reagent manufacturer, which makes an assumption that noncreatinine chromogen 
interference is a constant between samples.  Recalibrated Jaffe assays are referred to as 
compensated Jaffe methods. [5-7]  Compensated assays can produce inaccurate results 
since this method is based on the assumption that the amount of nonspecific chromogens 
is constant among all samples. 
 Enzymatic methods  are less likely to be affected by interferences than the Jaffe 
methods.[7] The enzymatic method used by Abbott Laboratories is based on a series of 
reactions. The first reaction is hydrolysis of creatinine to creatine. The creatine is then 
hydrolyzed by creatinase to sarcosine and urea.  Sarcosine is oxidized by sarcosine 
oxidase to form glycine, formaldehyde, and hydrogen peroxide. The hydrogen peroxide 
reacts with 4-aminoantipyrine and N-ethyl-N-sulphopropyl-m-toluidine (ESPMT) in the 
presence of peroxidase to create a color change. The resulting change in absorbance is 
measured at a wavelength of 548 nm and is proportional to the creatinine concentration of 
the sample.[2]  
 
Interferences 
Interfering substances are a significant issue in creatinine analysis.  As previously 
mentioned, Jaffe methods are susceptible to nonspecificity bias from a large number of 
interfering substances. The enzymatic methods are less susceptible to interferences and 
provide a more reliable estimate of creatinine and glomerular filtration rate (GFR).[7-9]  
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 Although the enzymatic method is more specific and less prone to endogenous 
interferences, interferences also occur in the enzymatic method. [5]  The substances 
known to interfere with the enzymatic and Jaffe assay are listed in Table 1.  Most likely, 
there are more interfering substances that have not yet been identified. 
 
Clinical Use of Creatinine Assays 
   Creatinine levels are used to assess renal function and monitor chronic renal 
diseases. Although plasma creatinine values can provide useful data to clinicians, the 
values can be difficult to interpret because the serum creatinine concentration is affected 
by factors other than renal filtration. For this reason, equations have been developed to 
estimate the glomerular filtration rate (eGFR).[10-13].  These equations estimate the eGFR 
based on creatinine and adjust for factors such as age, sex, race, and body size.[12, 14]  
Common formulas used to estimate eGFR are the Cockcroft and Gault, the MDRD[12] 
(Modification of Diet in Renal Disease), and the CKD-EPI[14] (Chronic Kidney Disease 
Epidemiology Collaboration) formulas. 
 The University of Utah Hospital Clinical Laboratory (UHCL) uses the CKD-EPI 
equation to estimate eGFR.  The CKD-EPI equation is:   
 
eGFRCKD-EPI = 141 × min (SC/k, 1)α × max (SC/k, 1)−1.209 × 0.993Age × 
1.018 (if female) × 1.159 (if black)    (Equation 1)[14] 
Where: 
  SC= Serum Creatinine 
k is 0.7 for females and 0.9 for males  
α is −0.329 for females and −0.411 for males  
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min indicates minimum of serum creatinine/k or 1  
max indicates maximum of serum creatinine/k or 1.  
eGFRCKD-EPI = (mL/min/1.73 m2) 
 
The MDRD equation is:   
 
eGFRMDRD =175 x (SCr-1.154) x (Age-0.203) x 0.742 (if female) x 1.212 (if 
black)        (Equation 2)[12] 
  Where: 
  SCr= Serum Creatinine 
  eGFRMDRD = mL/min/1.73m2 [14-16] 
 
The CKD-EPI and MDRD equations provide an estimate of the eGFR at single time 
points utilizing a patient’s age, race, gender, and plasma creatinine concentration.[15, 16]  
eGFR estimates can be inaccurate if any of the input variables are inaccurate (age, 
ethnicity, and body mass index).  Most importantly, eGFR estimates depend on the 
accuracy of creatinine measurements.[17-19] 
The accuracy of creatinine measurements can have significant impact on the 
accuracy of eGFR estimates. eGFR is inversely related to creatinine (see equations 1 and 
2). Because of the inverse relationship, the impact of imprecision and interfering 
substances is significant at low creatinine concentrations corresponding to eGFR values 
near the 60mL/min/1.73m2 threshold for identifying kidney disease, but is less important 
at high creatinine-low eGFR values characteristic of severe kidney disease.[5] For 
example, suppose a 30-year-old Caucasian male has his blood collected for creatinine 
analysis and eGFR calculation.  Under normal testing circumstances with no interfering 
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substances present, the patient’s serum creatinine is 1.3 mg/dL, resulting in a CKD-EPI 
eGFR calculation of 73 mL/min/1.73 m2. Due to the presence of a strong interfering 
substance, analysis of the sample yields a false high creatinine of 1.6 mg/dL.  The falsely 
elevated creatinine value results in a eGFR of 57 mL/min/1.73 m2.  Chronic kidney 
diseases are classified using the Kidney Disease: Improving Global Outcomes (KDIGO) 
scale which is based on eGFR (Table 2).  Using the correct eGFR (73 mL/min/1.73m2), 
this patient would be classified as G2 which corresponds to normal to mild decrease in 
kidney function. In the presence of the interfering substance (GFR = 57 mL/min/1.73m2), 
the patient would be  classified as a G3a, which corresponds to moderate kidney 
disease.[15]  Thus, an incorrect creatinine value can lead to misdiagnosis and improper 
treatment.  If an interfering substance caused a patient’s apparent eGFR to decrease 
below 60 mL/min/1.73 m2 for  three months or longer, the patient would be diagnosed as 
having chronic kidney disease.[10, 15, 20]  Misclassification is a particular risk for patients 
whose eGFR values are 60 mL/min/1.73m2, because diagnosis and treatment change at 
this point. Patients with creatinine values that are greatly elevated, resulting in a low 
eGFR, will see little change in the treatment and management of their disease (although 
continual assessment of eGFRs is important in determining the progress of CKD in these 
patients).[5] 
 
UHCL Validation and Manufacturer Control Precision Study 
 Precision studies conducted during the UHCL Abbott Architect ci8200 validation 
(analyzers 1 and 2) were performed using Bio-Rad  Multiqual 1 and 3 controls. Architect 
1 precision for the Jaffe method at mean concentrations of 0.53 mg/dL and 6.96 mg/dL 
had total CVs of 1.9% and 0.8%, respectively. Architect 1 precision for the enzymatic 
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method at mean concentrations of 0.59 mg/dL and 6.97 mg/dL had total CVs of 3.6% and 
2.0%, respectively. Architect 2 precision for the Jaffe method at mean concentrations of 
0.53 mg/dL and 6.98 mg/dL had total CVs of 2.0% and 1.2%, respectively. Architect 2 
precision for the enzymatic method at mean concentrations of 0.59 mg/dL and 7.02 
mg/dL had total CVs of 4.3% and 0.78%, respectively. It should be noted that the number 
of runs for each method is different; Jaffe N=18, enzymatic N=27.[21]  
In contrast, Abbott precision studies concluded that Jaffe methods have less 
precision than enzymatic methods. Precision for the Jaffe method at concentrations of 
1.20 mg/dL and 4.66 mg/dL had total CVs of 4.95% and 3.18%, respectively.[3] Precision 
for the enzymatic method at concentrations of 0.65 mg/dL, 1.83 mg/dL, and 6.60 mg/dL 
had total CVs of 3.17%, 1.72%, and 0.95%, respectively.[2] Table 3 lists a summary of the 
precision comparisons for the UHCL Validation and the manufacturer’s precision study. 
 
Reagent Comparison Studies 
 Method comparison studies found in published literature using the Jaffe and 
enzymatic creatinine methods have produced varied results. One study compared nine 
different analyzers and found reasonably good agreement between the enzymatic and 
Jaffe creatinine methods; however, this study found that the Jaffe method lacked 
specificity (endogenous substances that interfered with the reaction) and concluded that 
an alternative method may be needed in certain clinical situations (see Table 1 for 
common interferences).[5]  Method comparisons on patient groups with specific diagnoses 
found that values obtained using Jaffe methods were less than corresponding values using 
enzymatic methods in liver disorder patients (Jaffe mean difference: -8.9%; Spearman’s 
rho= -0.378, p <0.001; CV not available)[6]  and diabetics with ketoacidosis (Jaffe mean 
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difference: +50%, CV not available)[22]. A large study involving 144 participating 
laboratories examined 11 pairs of value assigned creatinine specimens ranging from 0.59-
2.96 mg/dL using Jaffe or enzymatic methodologies. The study found that Jaffe methods 
overestimated creatinine concentrations at 21%, 12% and 10% for target values of 0.59, 
0.83, and 1.06 mg/dL, respectively. Enzymatic methods obtained values that estimated 
differences at 0%, -1%, and -2%, respectively.[23]  These studies provide evidence that the 
Jaffe method is less accurate and the Jaffe method is affected by a wider range of 
interferences than the enzymatic method.    
 
Reagent Cost Comparison 
Cost is an important consideration in the selection of a laboratory method. Abbott 
list prices for the reagents are $580 for 1,875 creatinine Jaffe tests ($0.31 per test) and 
$1,509 for 750 enzymatic tests ($2.01 per test).[24] The testing volume of creatinine at 
UHCL is approximately 190,000 tests per year (Note: This does not include testing 
performed at Huntsman Cancer Hospital Laboratory or South Jordan Hospital 
Laboratory.) Costs based on yearly tests performed are $58,900 for Jaffe reagent and 
$381,900 for enzymatic.  The potential cost savings of performing creatinine testing with 




Risk is the product of two factors: 1) the probability of an event, and 2) the 
consequence associated with the event.[25]  The risk associated with the Jaffe method 
could be acceptable if either the probability of interference or the clinical consequences 
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associated with interferences were sufficiently low.  Unfortunately, neither of these risk 
components has been characterized for creatinine assays. Both risk components could 
vary by patient population.  Therefore, it may be possible to find patient populations for 
which the probability of interference or the consequence of inaccurate results is low.  
An interference will only have consequences if the observed change in 
measurement is considered both statistically and clinically significant.  To be classified as 
statistically significant, the magnitude of the change must be greater than the normal 
background variation.  To be “clinically significant,” a change in measurement must 




  Laboratory methods should be selected carefully, considering both costs and 
patient care.  The choice between the Jaffe and enzymatic methods present a tradeoff 
between cost and accuracy.  The enzymatic method is more costly but is also more 
accurate. 
It may be possible to find situations in which the Jaffe method provides 
acceptable performance.  The Jaffe could be acceptable in contexts where the probability 
of inaccurate results is low or if the consequences of inaccurate results could be 
minimized. For example, laboratories might be able to identify patient populations with 
different risk of interference and create separate testing panels for each population. It 
could be suggested that populations that are found to have a high prevalence of 
interfering substances have the option to order a different testing panel (Example: basic 
metabolic panel (BMP), comprehensive metabolic panel (CMP), etc.) that utilizes 
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enzymatic methodology. A second testing panel that utilizes the cheaper Jaffe 
methodology would be available to populations that are found to have a low prevalence 
of interfering substances. Using a structured ordering process based on prevalence of 
interference would give a laboratory the opportunity to save money using reliable testing 
with enzymatic methodology for at-risk patient populations.  
 
Study Objective 
The purpose of this study was to compare the creatinine and eGFR results from 
Jaffe and enzymatic creatinine methodologies in the University of Utah Healthcare 
outpatient clinic populations to analyze the prevalence of discordant results due to 
method interference and associated risk of implementing the Jaffe method. Many studies 
have reported on differences between the Jaffe and enzymatic technique.[26, 27]  Most 
studies have looked at discordances in creatinine values or estimated glomerular filtration 
rates using samples spiked with an interfering substance.  To our knowledge, no studies 
have used a risk evaluation framework to evaluate the prevalence of interferences in 
specific patient populations to identify any groups which are deemed unsafe to use the 
creatinine Jaffe method.  
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Table 1: List of Common Creatinine Interferences 
 
*Note that there are many unknown potential interferences for these assays. Table 1 lists common 















5-aminolevulinic acid Photodynamic 
Therapy Patients, 
Common 
Increased, Major None [32] 
Ascorbic Acid Any, Common Increased, Minor Decreased, 
Minor 
[5, 9, 33] 
Albumin, High Any, Common Increased, Minor None [5, 7, 34] 

















[5, 9, 33, 35] 
Cephalosporins Any, Common Increased, Minor-
Major 
None [5, 9, 33] 
Creatine Any, Common Increased, Minor None [5, 9] 
Glucose, High Diabetic Patients, 
Uncommon 
Increased, Minor None [5, 7, 9, 33] 
Hemoglobin F Neonates, Common Decreased, Major None [5, 7, 9, 34] 





IgG, High  Increased, Minor None [34] 




None [5, 9, 22, 33] 






Increased, Minor Increased, 
Moderate 
[33] 















Total Protein, High Any, Uncommon Increased, Minor None [33] 
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Table 2: Kidney Disease: Improving Global Outcomes (KDIGO) Classifications of 












Table 3: UHCL Validation and Abbott Diagnostics Precision data 
 
Architect 1 and 2 data are precision data from the UHCL reagent validation. 
Abbott Precision is the precision data obtained from the reagent package inserts 
summarizing precision data performed by Abbott Diagnostics. 
 
KDIGO Classification of CKD 
Glomerular Filtration Rate (GFR) 
Category GFR Degree of Renal Function 
G1 ≥90 Normal or High 
G2 60-89 Mild Decrease 
G3a 45-59 Mild to Moderate Decrease 
G3b 30-44 Mild to Severe Decrease 
G4 15-29 Severe Decrease 
G5 <15 Kidney Failure 
  Total CV Jaffe (N=18) 
Total CV Enzymatic 


















2.00% 1.20% 4.33% 0.78% 
  
  Total CV Jaffe  (N=80) Total CV Enzymatic (N=80) 





4.95% 3.18% 3.17% 1.72% 0.95% 
"N=" indicates number of runs performed 
  
 
MATERIALS AND METHODS 
 
Literature Review 
 The literature review was performed in two phases. The first phase consisted of 
searching for appropriate research articles using keyword searches in PubMed and 
Cumulative Index to Nursing and Allied Health (CINAHL). The following are the search 
terms that were used: enzymatic creatinine, enzymatic creatinine interferences, Jaffe 
creatinine, Jaffe creatinine interferences, creatinine interferences, enzymatic vs Jaffe, 
glomerular filtration rate, kidney function tests, CKD-EPI, MDRD, and compensated 
Jaffe. Additional references that were obtained outside of the keyword searches were the 
Abbott Jaffe and enzymatic reagent package inserts, UHCL Abbott Architect Validation 
data, Clinical Chemistry: Concepts and Applications, and Effects of Disease on Clinical 
Laboratory Tests: 4th Edition. Citations were entered into EndNote version 6. 
In the second phase, the research articles selected during the first phase were 
evaluated using Scopus to perform citation (forward) and reference (backward) searches. 
Duplicate references were removed using Endnote’s duplicate removal function followed 
by a manual search. 
 
Patient Population 
This study was based on samples collected from patients attending outpatient 
clinics both at the University Hospital and surrounding community clinics. All inpatient, 
cancer, emergency department, and surgical locations/clinics were excluded from this 
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study. The use of patient samples was approved by the University of Utah Institutional 
Review Board (IRB 00065210). 
 
Sample Collection 
   Clinic samples are typically collected and received in the lab during weekdays 
only (Monday through Friday). Samples were randomly selected from the daily volume 
of incoming samples. The ARUP Information Technology department developed a report 
that listed all creatinine assays performed on samples originating from hospital and 
community outpatient clinics from the previous day. The report included the sample 
accession, clinic name, and patient information (medical record number (MRN), age, sex, 
and race). Samples were randomly selected from this list using a random number 
generator in Microsoft Excel.  Each sample was assigned a random number between 
0.0000 to 1.0000 (four decimal places were used). The samples were then ordered 
according to the random number and the required number of samples was obtained by 
selecting samples in ascending order from the ordered list.  The MRNs of selected 
samples were compared against a list of previously selected samples. Samples drawn 
from patients that were previously sampled were excluded to ensure that each sample was 
from a unique patient.   
Samples were selected in two phases. In the first phase, 200 samples were 
collected at a rate of 20 per day.  In the second phase, 343 samples were collected at a 
rate of 50 samples per day (using the same random sample selection process that was 
used in the first phase).  All samples were retrieved from the UHCL’s refrigerated storage 
(4oC) and recentrifuged prior to analysis. Samples were analyzed one day after the 
samples were collected (testing occurred Tuesday through Saturday). 
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Overall, we selected 543 unique outpatient samples over a period of 45 days 
(7/31/2013 to 9/13/2013).  We obtained 248 samples from outpatient clinics located at the 




 Sample analysis was performed on the Abbott Architect c8000 analyzer. Each 
sample was tested by both Jaffe (kinetic alkaline picrate, Abbott Laboratories; Abbott 
Park, IL) and enzymatic (creatininase, Abbott Laboratories; Abbott Park, IL) methods. 
After centrifugation, samples were loaded onto Architect sample trays and batch ordered 
to perform simultaneous Jaffe and enzymatic testing.  
 Two levels of quality control (QC) were analyzed daily before any sample testing 
was performed. QC materials used for both methodologies were Bio-Rad MultiQual 
levels 1 and 3. For the Jaffe method, calibrations were performed every five days, as 
directed by the package insert, using Abbott MCC (Multi-constituent Calibrator). For the 
enzymatic method, calibrations were performed every 60 days, as directed by the package 
insert, using Abbott CCC (Clinical Chemistry Calibrator). 
 
Reagents 
 Abbott Jaffe Creatinine utilizes two reagents. Reagent 1 is sodium hydroxide and 
Reagent 2 is picric acid. The assay reaction occurs at an alkaline pH. The creatinine in the 
sample reacts with picrate to form a creatinine-picrate complex. The rate of increase in 
absorbance at 500nm due to the formation of this complex is directly proportional to the 
concentration of creatinine in the sample.[3] 
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 Abbott Enzymatic Creatinine  utilizes two reagents.  Reagent 1 contains Good’s 
buffer (pH 7.5), creatininase, sarcosine oxidase, catalase, and ESPMT. Reagent 2 
contains Good’s buffer (pH 7.5), creatininase, peroxidase, 4-aminoantipyrine. The assay 
reaction occurs when the creatinine is hydrolyzed by creatininase to creatine. Creatine is 
in turn hydrolyzed by creatinase to sarcosine and urea. Sarcosine is oxidized by sarcosine 
oxidase to glycine and formaldehyde, with the concomitant production of hydrogen 
peroxide.  The hydrogen peroxide reacts with 4-aminoantipyrine and ESPMT in the 
presence of peroxidase to yield a quinoneimine dye. The absorbance change at 548 nm is 
proportional to the creatinine concentration in the sample.[2]  
 
Creatinine Precision Measurement 
A 20 day precision study was performed using the Abbott Creatinine Jaffe and 
enzymatic assays on the Abbott Architect c8000. This precision study was performed to 
determine the precision of both reagents that only includes short-term sources of within-
run and between-run variation by eliminating variation due to different reagent lots, 
calibrations (enzymatic only), instruments, and operators.  
A “What If” analysis was performed within Excel using the community clinic 
Jaffe eGFR results to find an average creatinine concentration at a GFR of 60 
mL/min/1.73m2 (creatinine= 1.20 mg/dL). The “What If” analysis is an Excel tool that 
was used to evaluate what the creatinine concentrations for a given patient would be if 
the patients eGFR was changed to a specific value. This tool allowed for a reverse 
calculation for average creatinine concentration (and includes factors such as age, race 
and gender) to be determined by changing the eGFR calculation to solve for creatinine 
concentration in place of eGFR. 
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 The 20 day precision study was performed following Clinical and Laboratory 
Standards Institute (CLSI) guidelines and evaluated five different concentration pools of 
creatinine. Concentration pools were selected to include the range of clinic sample 
concentrations that were observed in the community clinic study (excluding outlier 
creatinine results greater than 5.0 mg/dL), and at points that were determined to have 
clinical significance (0.84 mg/dL and 1.20 mg/dL). Each patient pool was created using a 
minimum of 10 separate samples that were close to the desired concentration. The lowest 
concentration pool was diluted with saline to obtain the desired concentration. 
Creatinine sample concentration pools were made at 0.28 mg/dL, 0.79 mg/dL, 1.21 
mg/dL, 2.73 mg/dL, and 5.08 mg/dL. Each concentration pool was separated into 20 vials 
and frozen at -30oC. One sample at each concentration was measured in duplicate, daily, 
for 20 consecutive days. The total standard deviation (within run and between run) was 
determined from the 20 specimens at each concentration. 
eGFR precision was determined by simulation using the 20-day creatinine 
precision data. Measurement errors in serum creatinine were assumed to be normally 
distributed.  The variation in eGFR was determined by taking random samples from the 
creatinine distribution and calculating the corresponding eGFRs.  The standard deviation 
for eGFR for each pooled sample was determined from 10,000 simulated iterations.  
Standard deviations were determined for the eGFR predicted by the MDRD and CKD-
EPI methods using creatinine measured by the Jaffe and enzymatic methods. 
 
Statistical Analysis 
Creatinine results for both testing methodologies were compiled into an Excel 
spreadsheet that included sample accession, clinic name/location, MRN, age, sex, and 
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race. Calculations were performed using Stata 12 (Stata Corporation, College Station, 
TX). Statistical hypotheses were tested at the 5% significance level.  Correlation analysis 
was performed using orthogonal (Deming) regression using Minitab 16 (Minitab Inc., 
State College, PA). The observed and expected discordance rate was determined for 
eGFR measurements at the 60 mL/min/1.73m2 decision limit.   
 
Analysis of Discordant Creatinine Results 
Discordant creatinine measurements were identified by comparing the observed 
difference (Jaffe – enzymatic) to a measure of variation.  We used two different measures 
of variation to determine discordance.  The first method was based on the observed 
variation of differences. The second method was based on the predicted variation due to 
imprecision in measurement (determined by 20 day precision study). 
Discordance based on observed variation was standardized using the standard 
deviation of the observed differences: 
 
    z!,!"!"# = !!!!!!!,!"!"#     (Equation 3) 
 
       
where z!,!"!"#  is the standardized difference in creatinine values obtained by the Jaffe and 
enzymatic methods, C! is the creatinine concentration obtained by the Jaffe method, C! is 
the creatinine concentration obtained by the enzymatic method, and S!,!"!"#  is the standard 
deviation based on the observed differences, C! −   C!    and includes all sources of error 
(measurement error, interferences, etc.). Cases with |z!,!"!"#| > 1.96 were defined as 
discordant. By, definition, this criterion will classify 5% of cases as discordant.  Using 
this definition, discordant results could be caused by imprecision or interference.   
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Discordance based on measurement variation was standardized using the 
predicted standard deviation of the differences due to measurement imprecision: 
 
       z!,!"!"#$ = !!!!!!!,!"!"#$      (Equation 4) 
 
where z!,!"!"#$ is the standardized difference in creatinine values obtained by the Jaffe and 
enzymatic methods, S!,!"!"#$  (C!) =    s!,!!"#$(C!) ! + s!,!!"#$(C!) !   is the standard 
deviation of the creatinine difference due to measurement imprecision.  s!,!!"#$(𝐶!) and s!,!!"#$(𝐶!) are the total measurement variance (between day + between run + between 
sample) associated with the Jaffe and enzymatic methods, respectively, at a particular 
creatinine level as determined by the reference (enzymatic)  method.  Cases with |z!,!"!"#$| 
> 1.96 were defined as discordant. s!,!!"#$(C!) ! and s!,!!"#$(C!) !  were obtained by 
linear interpolation of the standard deviation data obtained from the precision studies.  S!,!"!"#$  (C!) represents the predicted imprecision due to measurement error alone and does 
not include the impact of other factors such as interferences.  When interferences are 
absent, this definition would define 5% of cases as discordant. When interferences are 
present, this definition would classify more than 5% of cases as discordant. By definition, 
interferences cause measurement errors that are greater than the measurement 
imprecision.  Thus, by using a definition of discordance based on imprecision, the 




Analysis of Discordant eGFR Results 
As with creatinine measurements, we identified eGFR discordances using both 
predicted measurement error and the distribution of observed differences. Discordant 
eGFRs based on observed differences were determined using the MDRD and CKD-EPI 
equations:   
 
     z!(!),!"!"# = !!,!!!!,!!!(!),!"!"#                (Equation 5) 
 
where z!(!),!"!"#  is the standardized difference in eGFR obtained by the Jaffe and 
enzymatic methods using method M (M=MDRD or CKD-EPI), G!,! is the eGFR 
concentration obtained by the Jaffe method using eGFR method M, G!,! is the eGFR 
obtained by the enzymatic method, and S!(!),!"!"#  is the standard deviation based on the 
observed differences, G!,! −   G!,! .   
Discordant eGFRs based on imprecision between the Jaffe and enzymatic 
methods were standardized using the standard deviation of the difference due to 
measurement: 
 
      z!(!),!"!"#$ = !!!!!!!(!),!"!"#$      (Equation 6) 
 S!(!),!"!"#$   (C!) =    s!(!),!!"#$ (C!) ! + s!(!),!!"#$ (C!) !    (Equation 7) 
 
where z!",!"!"#$  is the standardized difference in eGFR obtained by the Jaffe and enzymatic 
methods, S!(!),!"!"#$   (C!)   is the standard deviation of eGFR difference due to measurement, 
and  s!,!!"#$ and s!,!!"#$ are the total measurement variance (between day + between run + 
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between sample) associated with the Jaffe and enzymatic methods, respectively.  Cases 
with z!(!),!"!"#$  > 1.96 were defined as discordant. s!(!),!!"#$ (C!) and s!(!),!!"#$ (C!) were 
obtained by simulation as described above. s!(!),!!"#$ (C!) and s! ! ,!!"#$ C!   are the predicted 
imprecision in eGFR due to measurement error alone and do not include the impact of 
other factors such as interferences and operator error. 
 
Expected Discordance Rate 
The expected discordance rate was measured as follows: 
Let:  
 𝑥 = the true underlying value for the analyte  
 𝑋!= the observed value using method M, including all sources of error  
 𝑋!!"#$= the observed value using method M, including measurement error only 
 𝑏!(𝑥) = the bias in 𝑋!!"#$  as a function of 𝑥  𝑠!(𝑥) = the precision profile of method 𝑀 (standard deviation of 𝑋!!"#$as a 
function of  𝑥) 
 𝑐 = the diagnostic cutoff   𝑧!   𝑥 = !!!!(!)!!!!(!)  = the standardized distance of the mean of method 𝑀 from 
the cutoff 𝐹! 𝑧|𝑥  = the cumulative distribution function for the measurement error for 
laboratory method   𝑀, given the true value of the underlying analyte 𝑥 




Let 𝐴!,! be the event that the two laboratory methods agree with respect to the 
diagnostic cutoff. Given two observations on the same sample, there are two ways 
that the results of the methods can agree (see Figure 1):  
                                                                  𝐴!,! = 1  𝑖𝑓   𝑋! < 𝑐)  AND  (𝑋! < 𝑐)     OR   (𝑋! > 𝑐)  AND  (𝑋! > 𝑐)0  𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒   
(Equation 8) 
 
The agreement rate is: 
 
    𝐴!,!!"# = 𝑃 𝐴!,!  	   	   (Equation 9)	   	  
 
If imprecision is the only source of variation, then: 




Given a   true value, 𝑥, the probability of agreement between two observations with 
respect to the cutoff is: 




The expected agreement rate with respect to the cutoff is: 
 𝐴!,!!"#$ = 𝑃 𝐴!,!!"#$ =    P 𝐴!,!!"#$|𝑥   𝑔 𝑥 𝑑𝑥!! 	  = 𝐹!(𝑐|𝑥)𝐹! 𝑐|𝑥 +    1− 𝐹!(𝑐|𝑥) 1− 𝐹!(𝑐|𝑥)    𝑔 𝑥 𝑑𝑥!! 	  	  = 𝛷(−𝑧! 𝑥 )𝛷 −𝑧! 𝑥 +    1− 𝛷(−𝑧!(𝑥) 1−!!
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where the last step is based on the assumption that the measurement error 𝑋!!"#$ is 
normally distributed with mean 𝑏!(𝑥) and standard deviation 𝑠!(𝑥) when the true value 











20 Day Creatinine Precision Profile 
 
The precision profiles are presented in Table 4. The Jaffe method had greater 
precision than the enzymatic method, except at the lowest concentration level (0.28 
mg/dL). The standard deviation of the difference between the Jaffe and enzymatic 
methods ranged from 0.012 mg/dL (SCr = 0.278 mg/dL) to 0.71 mg/dL (SCr = 5.080 
mg/dL). 
 
Correlation of Creatinine Measurements 
Orthogonal (Deming) regression analysis showed no significant difference 
between the Jaffe and enzymatic methods (Figure 1).  The slope was 1.006 (95% CI: 
0.998, 1.103) and the intercept was -0.005 (95% CI: -0.015, 0.006). 
 
Discordant Creatinine Measurements 
The distribution of differences in creatinine measurements between the Jaffe and 
enzymatic method are shown in Figure 2.  The average difference (bias) between the 
methods was -0.007 mg/dL.  Forty percent of the differences exceeded the bounds (two 
standard deviations) predicted by measurement error alone (Figure 1). These were 
classified as discordant results.  There was no association between discordant results and 
clinic location (χ!! = 1.3,  p=0.53).  Five percent of the differences exceeded the bounds 
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based on observed differences.  There was no association between this set of outliers and 
outpatient clinic type (χ!! = 0.02,  p=0.89).	  	  
	  
eGFR Precision Profile 
The precision profiles for the eGFR are presented in Figure 3.  When using the 
CKD-EPI method, the predicted standard deviation for the difference in eGFR (Jaffe vs. 
enzymatic) ranged from 0.1 mL/min/1.73m2 (CV= 1.25%) to 3.5 mL/min/1.73m2 (CV= 
2.78%), at eGFR levels of 8 and 126 mL/min/1.73m2, respectively.  The precision profile 
for CKD-EPI was discontinuous when the eGFR was greater than 80 mL/min/1.73m2 
because of the minimum and maximum functions in the estimating equation.  When using 
the MDRD method, the predicted standard deviation for the difference in eGFR (Jaffe vs. 
enzymatic) ranged from 0.1 mL/min/1.73m2 (CV= 1.25%) to 5.8 mL/min/1.73m2 (CV= 
3.28%) at eGFR levels of 8 and 177 mL/min/1.73m2, respectively. 
 
Correlation of eGFR Measurements 
Orthogonal (Deming) regression showed significant differences between eGFRs 
based on the Jaffe and enzymatic methods (Figure 4).  For the CKD-EPI method, the y-
intercept for the Jaffe-enzymatic correlation was 2.66 (95% CI: 1.35, 3.98) and the slope 
was 0.97 (95% CI: 0.95, 0.99).  For the MDRD method, the y-intercept was 6.49 (95% 
CI: 4.8, 8.2) and the slope was 0.90 (95% CI: 0.88, 0.92).   
 
Discordant eGFR Measurements 
Discordant results for the CKD-EPI method are summarized in Table 5. Forty 
percent (217 of 543) of the differences in eGFR (Jaffe - enzymatic) exceeded two 
standard deviations of the predicted measurement error. With the CKD-EPI equation, 
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3.9% of the differences (21 of 543) exceeded the Bland-Altman limits of agreement 
(Figure 5).  At the 60 mL/min/1.73m2 decision limit, 3.1% (17 of 543) of differences 
resulted in a change of classification.  Of these, six were within the expected 
measurement variation and 11 exceeded two standard deviations of the difference based 
on measurement error.  The predicted discordance rate at the 60 mL/min/1.73m2 decision 
limit was 3.3% (17.7 of 543).  The difference between the predicted and actual 
discordance at the 60 mL/min/1.73m2 decision limit was not statistically significant (χ!! = 
-0.13, p=0.89).   
Discordant results for the MDRD method are summarized in Table 6. Forty 
percent (217 of 543) of the differences in eGFR (Jaffe – enzymatic) exceeded two 
standard deviations of the predicted measurement error of the difference. With the 
MDRD equation, 4.8% of the differences (26 of 543) exceeded the Bland-Altman limits 
of agreement (Figure 5).  At the 60 mL/min/1.73m2 decision limit, 4.8% (26 of 543) of 
the observed eGFR differences resulted in a change in classification. Of these, nine were 
within the expected measurement variation and 17 exceeded two standard deviations of 
the difference based on measurement error.  The predicted discordance rate at the 60 
mL/min/1.73m2 decision limit was 4.4% (24.2 of 543).  The difference between the 
predicted and actual discordance at the 60 mL/min/1.73m2 decision limit was not 
statistically significant (χ!! = 0.31, p=0.76).  The MDRD discordant differences were 
highly correlated with CKD-EPI discordant differences (ρ = 0.97, p =<0.001) 
 
Expected vs. Actual Discordance Rate 
 The expected discordance rates were calculated for both eGFR equations using 
Equation 12 and were calculated at decision limits of 30 mL/min/1.73m2, 
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45mL/min/1.73m2, and 60mL/min/1.73m2 and are summarized in Tables 7 and 8. For the 
CKD-EPI equation, the observed discordance rate was 0.37, 1.47 and 3.13, respectively. 
The expected discordance rate from imprecision (enzymatic only) was 0.28, 0.82, and 
1.46, respectively. The estimated discordance rate due to factors other than imprecision 
was 0.02 , 0.62, and 1.72, respectively. 
 For the MDRD equation, the observed discordance rate was 0.37, 0.74, and 4.79, 
respectively. The expected discordance rate from imprecision (enzymatic only) was 0.26, 
0.78, and 1.66, respectively. The estimated discordance rate due to factors other than 






Table 4: Precision Profile for Creatinine Assays 




Table 5: Cross-Tabulation of Discordant eGFR Results using CKD-EPI 
Discordance  Type Discordant Result 
Decision Limit   Tot
al 





Based on Measurement 
Error   
No 320 6 326 
Yes 206 11 217 
Total  526 17 543 
 




No 505 17 522 
Yes 21 0 21 
Total 526 17 543 
	  
Discordances are classified by discordance type and with respect to reclassification at 
decision limits.  Discordance based on measurement error is determined relative to limits 
calculated by Equation 7.  Discordance based on observed differences is determined 
relative to limits calculated by Equation 5.   
	  
 
Creatinine Level (mg/dL) 
Standard 




Difference Enzymatic Jaffe Enzymatic Jaffe 
0.278 0.288 0.012 0.008 0.009 2.91 3.00 
0.791 0.772 0.018 0.014 0.011 1.71 1.43 
1.214 1.126 0.029 0.021 0.020 1.71 0.81 
2.734 2.822 0.042 0.035 0.023 1.27 0.81 
5.080 5.128 0.071 0.059 0.040 1.16 0.78 
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Table 6: Cross-Tabulation of eGFR Discordant Results using MDRD 
Discordance  Type Discordant Result 
Decision Limit   Total 





Based on Measurement 
Error   
No 317 9 326 
Yes 200 17 217 
Total  517 26 543 
     
Based on Observed 
Differences 
(Bland-Altman)  
No 491 26 517 
Yes 26 0 26 
Total 517 26 543 
 
Discordances are classified by discordance type and with respect to reclassification at 
decision limits.  Discordance based on measurement error is determined relative to limits 
calculated by Equation 7.  Discordance based on observed differences is determined 
relative to limits calculated by Equation 5.   
 
Table 7: Expected vs. Actual Discordance Rate using CKD-EPI 
 
CKD-EPI 
Decision Limit, mL/min/1.73m2  
30  45 60   
A Observed discordance 
rate 
 
0.37 1.47 3.13 









1.01 – 2.02 
C Expected discordance rate 








D Incremental discordance 








E Estimated discordance 
rate due to factors other 

















Table 8: Expected vs. Actual Discordance Rate using MDRD 
 MDRD 
Decision Limit, mL/min/1.73m2 
30  45 60   
A Observed discordance 
rate 
 
0.37 0.74 4.79 
B Expected discordance rate 








C Expected discordance rate 








D Incremental discordance 







E Estimated discordance 
rate due to factors other 








* = discordance rate we would observe if we compared enzymatic against enzymatic 













Figure 1: Correlation of Jaffe and enzymatic methods. The solid line indicates perfect 
concordance and the dashed line is the best linear fit comparing Jaffe and enzymatic 
creatinine values. Lines observed represent perfect concordance. n=543 
  












Figure 2: Difference plot for creatinine. The solid lines represent two standard deviations 
of the difference between Jaffe and enzymatic methods based on measurement error   𝑠!,!"   (𝐶!) =    𝑠!,!! (𝐶!)+ 𝑠!,!! (𝐶!)  .  The dashed lines represent two standard deviations 












Figure 3: Precision profile for eGFR measurements.  The figure shows the standard 
deviation of the eGFR as a function of eGFR for the CKD-EPI (left panels) and MDRD 
(right panels) methods. The top, middle, and bottom rows correspond to the enzymatic, 
Jaffe and error of the difference (Jaffe – enzymatic), respectively. All data (age, sex, and 
race) are aggregated.  The discontinuity in the CKD-EPI plots is due to the maximum and 
















Figure 4: Correlation of Jaffe eGFR and enzymatic eGFR. Left Panel:  eGFR based on 
CDK-EPI equation.  Right panel:  eGFR based on MDRD equation.  Solid line:  Line of 





























0 50 100 150 200
eGFR, Enzymatic
MDRD









Figure 5: Difference plots for the eGFR by CKD-EPI and MDRD. The outer lines are the 
Bland-Altman (difference) limits of agreement.  The inner lines are the estimated 









This study examined the differences between serum creatinine results and 
resultant eGFRs based on the use of enzymatic and Jaffe methods. The study determined 
the incremental discordances that would arise from the use of the Jaffe method. This 
study used two different criteria, with different levels of stringency, to define discordant 
results for: 1) criteria based on observed differences between the Jaffe and enzymatic 
methods; 2) criteria based on the estimated measurement error of the difference between 
the Jaffe and enzymatic methods. These criteria were based on potential sources of 
variation that lead to discordant results. 
Multiple factors can create variability in creatinine results. These are categorized 
as measurement error (imprecision) and nonmeasurement error (sample interferences). 
Measurement error and nonmeasurement error correspond to common cause and special 
cause variation in the quality control literature. The goal of this study was to estimate the 
discordance rate due to interferences in the Jaffe method and to separate out the 
discordances due to measurement variation.  
Unexpectedly, the imprecision of the Jaffe method was lower than the enzymatic 
method at four of the five concentrations in the 20-day precision profile (Table 4).  This 
is in contrast to the manufacturer precision data provided by Abbott Diagnostics (Table 
3). Although the precision data obtained from the UHCL 20-day precision profile was 
limited to a smaller data size (Table 4, 40 data points per creatinine concentration level 
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for the UHCL precision compared to 80 data points per concentration level for the Abbott 
precision), the UHCL precision profile strictly adhered to CLSI precision guidelines to 
ensure the most accurate results possible. Also, the UHCL precision profile evaluated 
five total concentrations concurrently with both methods, whereas the Abbott precision 
data evaluated two concentrations for the Jaffe method and three concentrations for the 
enzymatic. Neither of these Abbott precision studies evaluated the Jaffe and enzymatic 
methods concurrently. 
The most stringent comparison criterion in this study was based on the estimated 
measurement error of the difference between the Jaffe and enzymatic eGFRs (Equations 
6 and 7). This criterion was based on precision studies for the Jaffe and enzymatic 
methods. The criterion is stringent because the estimated standard deviation only includes 
short-term sources of within-run and between-run variation. For example, the criterion 
used eliminates variation due to different reagent lots, calibrations, instruments, and 
operators. This produced a lower bound on the standard deviation of the measured 
differences and an upper bound for the percentage of differences that were due to all 
nonmeasurement factors.  Approximately 40% of the differences between the eGFR 
based on the Jaffe and enzymatic method could be attributed to nonmeasurement 
variation.  Although this criterion enabled an upper bound on the discordance rate to be 
set, it is not clear what proportion of such discordances is clinically significant because 
the threshold for discordance is so low. 
The least stringent comparison criterion was based on the observed differences 
between the eGFRs produced by the Jaffe and enzymatic methods (Equation 5).  This 
criterion included all sources of variation which produced a lower bound for the 
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discordance rate due to interference.  Using this criterion for both the CKD-EPI and 
MDRD equations, approximately 5% of differences were classified as discordant (Tables 
5 and 6).  
Figure 6 illustrates the discordances observed at the 60 mL/min/1.73m2 decision 
limit for both eGFR calculation methods. A result was classified as discordant if the 
enzymatic eGFR and Jaffe eGFR classified cases differently with respect to a decision 
limit. Each line in the graph represents the difference in the Jaffe and enzymatic result of 
a single sample as it crosses over the 60 mL/min/1.73m2 decision limit (see Equation 7). 
Discordances with less than two standard deviations represent normal measurement 
variation and are marked with circles. Discordances with greater than two standard 
deviations represent samples with the presence of some form of sample interference and 
are marked with triangles.  The discordances marked with triangles represent significant 
changes in the eGFR at critical decision limits and may result in a change of care to the 
detriment of the patient.   
The number of discordant results varies by which eGFR calculation is used. Using 
the CKD-EPI calculation, a total of 17 discordant results are recorded at the 60 
mL/min/1.73m2 decision point. Using the MDRD calculation, a total of 26 discordant 
results are recorded at the 60 mL/min/1.73m2 decision point. The magnitude of individual 
discordances is also greater with the MDRD equation and is visualized in Figure 6. The 
importance of discordant results at this decision limit is the reclassification of renal 
function (Table 2) and, more importantly, potential for change in disease treatment. 
Comparing the estimated discordance rates using the CKD-EPI and MDRD 
equations shows a small degree of variability at different eGFR decision limits (Tables 7 
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and 8). The MDRD equation presented a lower observed discordance rate at the 30 and 
45 mL/min/1.73m2 decision limits. The CKD-EPI equation presented a lower observed 
discordance at the 60 mL/min/1.73m2 decision limit, as well as a lower estimated 
discordance rate due to factors other than imprecision at the 30 and 60 mL/min/1.73m2 
decision limits. 
The number of observed discordant eGFR results slightly varies based upon 
which calculation is used. Using the CKD-EPI equation, 217 of 543 of eGFR results were 
discordant based upon imprecision, and 21 of 543 of eGFR results were discordant based 
upon observed differences (Bland-Altman limits of agreement). Using the MDRD 
equation, 217 of 543 discordant results were observed based upon measurement error and 
26 of 543 discordant results were observed based upon observed differences (Bland-
Altman). The MDRD equation shows lower correlation (Figure 4) of results and a greater 
magnitude of variation (Figures 5 and 6) than the CKD-EPI equation.  
The question arises, “Are the costs savings worth the risk of implementing the 
Jaffe methodology?” This study determined that 40% of the differences in eGFR 
exceeded two standard deviations of the estimated measurement error (most stringent 
criteria), and only 5% of the differences exceeded two standard deviations based on 
observed differences (least stringent criteria).  Risk is the product of two components: 1) 
the probability of an event; and 2) the consequence associated with the event. This study 
has determined the probability of a discrepant creatinine result. Future research to be 
conducted on this topic is to determine the clinical consequence of a discrepant creatinine 
result. 
This study is the first step in providing cost savings while continually improving 
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patient care. The potential cost savings for the UHCL switching to the Jaffe method for 
outpatient and clinic sample testing is tremendous. With the recent implementation of the 
Affordable Care Act (ACA), and its associated laboratory reimbursement cuts,[28-31] 
laboratories are being driven to find cost savings.  However, changes in the laboratory to 
provide cost savings should not come at the expense of patient care. Should this method 
be deemed safe for use, UHCL would achieve substantial savings. Further discussion 
between laboratory management and physicians is still required to determine if the less 







Figure 6: Discordances at decision limits. Each line represents the difference between the 
Jaffe eGFR and enzymatic eGFR (indicated by marker) of a single patient. The vertical 
lines indicate the decision limit and two standard deviations of the difference (Jaffe-
enzymatic) due to measurement error (Equation 7) at the decision limit.  Differences that 
are greater than two standard deviations of the measurement error are indicated by 
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